Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

7 treatments under study, led by Surgery

Research Leaders

12 sponsors active, led by Universität Münster

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (3)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06665724Phase 1Completed

Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

NCT01392209Phase 1Completed

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

NCT01339039Phase 1Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Showing all 3 trials

Research Network

Common Treatments

  • Surgery1
  • Bevacizumab1
  • Cv011
  • 5aminolevulinic Acid Hydrochloride Gliolan1
  • Plerixafor1

Active Sponsors

  • Universität Münster1
  • Columbia University1
  • Brigham and Women's Hospital1
  • Patrick Y. Wen, MD1
  • Memorial Sloan Kettering Cancer Center1

Top Investigators

Related Conditions

  • Anaplastic Astrocytoma Aa3
  • Anaplastic Mixed Gliomas1
  • High Grade Glioma Glioblastoma Gbm1
  • Mixed Anaplastic Oligoastrocytoma Aoa1
  • Malignant Glioma1

Activity Timeline